更昔洛韦联合炎琥宁治疗小儿手足口病疗效观察

Curative Effect Observation of the Combined Therapy of Ganciclovir and Yanhuning in Treating Hand,Foot and Mouth Disease

目的了解更昔洛韦联合炎琥宁治疗小儿手足口病的疗效和安全性。方法将80例手足口病患儿随机分为两组,治疗组给予更昔洛韦针(5mg/kg·d)及炎琥宁针(10mg/kg·d),每日1次,溶于5%葡萄糖溶液中静脉滴注。对照组给予利巴韦林针(10mg/kg·d)及VitC针(100mg/kg·d)溶于5%葡萄糖溶液中静脉滴注,每日1次。结果治疗组总有效率为95.0%,对照组总有效率为67.5%,两组有效率差异具有统计学意义(χ2=9.9282,P<0.01);两组患儿的退热时间、皮疹消退时间经比较,亦可见差异有统计学意义,t值分别为2.295(P<0.05)、7.227(P<0.01)。结论更昔洛韦联合炎琥宁治疗小儿手足口病安全有效,未发现明显不良反应,值得临床推广。

OBJECTIVE To observe the clinical curative effect and safety of the combined therapy of ganeiclovir and Yanhuning in treating hand, foot and mouth disease（HFMD） patients. METHODS 80 cases of children patients diagnosed with HFMD were randomly divided into two groups. The patients in treatment group were treated with a combination of Ganeiclovir （5 mg/kg, d）and Yanhuning （10mg/kg. d）cliluted with glucose injection once a day, while the control group was treated with a combination of ribavirin（10 mg/kg-d） and VitC （100mg/kg.d）cliluted with Glucose injection once a day. RESULTS The total effective rate of treatment group is 95.0%, and that of the control group is 67.5%. The deference is statistically significant（x2=9.928 2, P〈0.01）. Comparing the fever subsiding time and rash disaPPearance time of the two groups after treatment, the deference is statistically significant （t=2.295, P〈0.05 ; t= 7.227, P〈0.01）. CONCLUSIONS Combined therapy of ganciclovir and Yanhuning in treating HFMD patients is effective and safe, worthy of clinical promotion.